Catabasis Pharmaceuticals, Inc. (CATB) Upgraded at Zacks Investment Research

Zacks Investment Research upgraded shares of Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) from a hold rating to a buy rating in a research note published on Thursday. They currently have $1.75 price objective on the biotechnology company’s stock.

According to Zacks, “Catabasis Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of therapeutics for treatment of inflammatory, immunological and metabolic diseases. Its product development pipeline includes CAT-1004, CAT-2000 series including CAT-2054 and CAT-2003, CAT-4001 as well as various programs which are in different clinical-stage. Catabasis Pharmaceuticals, Inc. is based in Cambridge, Massachusetts. “

CATB has been the subject of a number of other research reports. Cowen and Company reissued a market perform rating and set a $2.00 target price on shares of Catabasis Pharmaceuticals in a research report on Friday, October 6th. Oppenheimer Holdings, Inc. cut their target price on shares of Catabasis Pharmaceuticals from $9.00 to $4.00 and set an outperform rating for the company in a research report on Tuesday, August 15th. HC Wainwright boosted their target price on shares of Catabasis Pharmaceuticals from $8.00 to $9.00 and gave the stock a buy rating in a research report on Monday, August 14th. CIBC reissued an outperform rating and set a $7.00 target price (up previously from $4.00) on shares of Catabasis Pharmaceuticals in a research report on Thursday, October 5th. Finally, Citigroup Inc. reissued a hold rating and set a $1.50 target price on shares of Catabasis Pharmaceuticals in a research report on Friday, September 29th. Two equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The stock currently has an average rating of Buy and a consensus price target of $4.89.

Catabasis Pharmaceuticals (CATB) traded down $0.03 during mid-day trading on Thursday, hitting $1.62. 191,486 shares of the company traded hands, compared to its average volume of 346,129. Catabasis Pharmaceuticals has a 1-year low of $1.08 and a 1-year high of $5.51.

Catabasis Pharmaceuticals (NASDAQ:CATB) last released its quarterly earnings data on Thursday, November 9th. The biotechnology company reported ($0.31) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.33) by $0.02. The business had revenue of $0.25 million during the quarter. research analysts forecast that Catabasis Pharmaceuticals will post -1.42 earnings per share for the current year.

WARNING: This news story was originally published by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this news story on another site, it was illegally copied and reposted in violation of US & international copyright and trademark law. The correct version of this news story can be accessed at https://sportsperspectives.com/2017/11/19/catabasis-pharmaceuticals-inc-catb-upgraded-at-zacks-investment-research.html.

Several institutional investors and hedge funds have recently made changes to their positions in CATB. Renaissance Technologies LLC acquired a new position in shares of Catabasis Pharmaceuticals during the first quarter valued at about $106,000. Oppenheimer & Co. Inc. raised its position in shares of Catabasis Pharmaceuticals by 33.3% during the second quarter. Oppenheimer & Co. Inc. now owns 120,000 shares of the biotechnology company’s stock valued at $169,000 after buying an additional 30,000 shares during the last quarter. Virtu KCG Holdings LLC acquired a new position in shares of Catabasis Pharmaceuticals during the second quarter valued at about $271,000. Finally, Wedbush Securities Inc. raised its position in shares of Catabasis Pharmaceuticals by 2,368.6% during the third quarter. Wedbush Securities Inc. now owns 251,802 shares of the biotechnology company’s stock valued at $534,000 after buying an additional 241,602 shares during the last quarter. 32.53% of the stock is owned by institutional investors and hedge funds.

Catabasis Pharmaceuticals Company Profile

Catabasis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics based on its Safely Metabolized And Rationally Targeted (SMART), a linker drug discovery platform. The SMART linker drug discovery platform enables to engineer product candidates that can modulate multiple targets in a disease.

Get a free copy of the Zacks research report on Catabasis Pharmaceuticals (CATB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Catabasis Pharmaceuticals (NASDAQ:CATB)

Receive News & Ratings for Catabasis Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catabasis Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply